Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
Stock Information for Eiger BioPharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.